Natriuretic peptide testing in emergency settings

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 11, 2008, Pages 1543-1549

  Ordonez Llanos, Jordi ^a,b   Merce Muntanola, Javier ^a   Santalo Bel, Miquel ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Acute heart failure; B type natriuretic peptides; Cost benefit; Diagnostic gray zone; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ACUTE DISEASE; ADULT; AGED; ANXIETY DISORDER; BLOOD LEVEL; CLINICAL LABORATORY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DYSPNEA; ECHOCARDIOGRAPHY; EMERGENCY WARD; HEART DISEASE; HEART FAILURE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LUNG DISEASE; MAJOR CLINICAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PLASMA; POINT OF CARE TESTING; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOASSAY;

CLINICAL CHEMISTRY TESTS; COST-BENEFIT ANALYSIS; DYSPNEA; EMERGENCY SERVICE, HOSPITAL; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; PROGNOSIS;

EID: 56549095779     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.298     Document Type: Conference Paper

References (25)

1. Togashi K, Hirata Y, Ando K, Takei Y, Kawakami M, Marumo F. Brain natriuretic peptide-like immunoreactivity is present in human plasma. FEBS Lett 1989;250:235-7.
2. Gillespie ND, McNeill G, Pringle T, Ogston S, Struthers AD, Pringle SD. Cross sectional study of contribution of clinical assessment and simple cardiac investigations to diagnosis of left ventricular systolic dysfunction in patients admitted with acute dyspnoea. Br Med J 1997;314:936-40.
3. Knudsen CW, Omland T, Clopton P, Westheim A, Abraham WT, Storrow AB. Diagnostic value of B-type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. Am J Med 2004;116:363-8.
4. Rihal CS, Davis KB, Kennedy JW, Gersh BJ. The utility of clinical, electrocardiographic, and roentgenographic variables in the prediction of left ventricular function. Am J Cardiol 1995;75:220-3.
5. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, for the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
6. Knudsen CW, Clopton P, Westheim A, Klemsdal TO, Wu AH, Duc P, et al. Predictors of elevated B-type natriuretic peptide concentrations in dyspneic patients without heart failure: an analysis from the Breathing Not Properly multinational study. Ann Emerg Med 2005;45:573-80.
7. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Am J Cardiol 2005;95:948-54.
8. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, Lopez L, Cotes C, Bellido J, et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail 2004;6:301-8.
9. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. The International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330-7.
10. Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med 1992;21:669-74.
11. Worster A, Balion CM, Hill SA, Santaguida P, Ismaila A, McKelvie R, et al. Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: a systematic review. Clin Biochem 2008;41:250-9.
12. Tang WH, Francis GS, Morrow DA, Newby KL, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Clin Biochem 2008;41:210-21.
13. Taylor JA, Christenson RH, Rao K, Jorge M, Gottlieb SS. B-Type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 2006;152:1071-6.
14. Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR, Lainchbury JG, Richards AM, Ordoñez-Llanos J, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 2007;167:400-7.
15. van Kimmenade RR, Pinto YM, Bayes-Genis A, Lainchbury JG, Richards AM, Januzzi JL Jr. Usefulness of intermediate aminoterminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol 2006;98:386-90.
16. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 2002;39:131-8.
17. Januzzi JL Jr, Sakhuja R, O'Donoghue M, Baggish AL, Anwaruddin S, Chae CU, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med 2006;166:315-20.
18. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91.
19. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;110:2168-74.
20. Schou M, Gustafsson F, Nielsen PH, Madsen LH, Kjaer A, Hildebrandt PR. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 2007;9:68-74.
21. Bruins S, Fokkema MR, Romer JW, Dejongste MJ, van der Dijs FP, van den Ouweland JM, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-8.
22. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH, Cannon CP, National Academy of Clinical Biochemistry; IFCC Committee for Standardization of Markers of Cardiac Damage. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of heart failure. Clin Biochem 2008;41:222-6.
23. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
24. Siebert U, Januzzi JL Jr, Beinfeld MT, Cameron R, Gazelle GS. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 2006;98:800-5.
25. Moe GW, Howlett J, Januzzi JL, Zowall H; Canadian Multicenter Improved Management of Patients with Congestive Heart Failure (IMPROVE-CHF) Study Investigators. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007;115:3103-10.